Lu et al. performed a genome-wide screen of HCC cells treated with or without Lenvatinib and identified NF1 and DUSP9 as key factors for Lenvatinib resistance (Lu et al., 2021). This evidence concerns the gene DUSP9 and hepatocellular carcinoma.